AnaBios acquired human primary and cell culture media group Cell Systems for an undisclosed price in a deal that gives the San Diego-based preclinical CRO an expanded portfolio of human tissue and cells.
AnaBios Corporation, a leading preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to...
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has awarded AnaBios a $1,734,409 Small Business Innovation Research (SBIR) grant through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to advance the development of its novel analgesic, ANB-504. The new compound was initially developed using PhaseX®, AnaBios' unique human-based translational paradigm, which helps overcome the limitations of the current pain drug discovery strategy by generating human-relevant and clinically predictive data at the preclinical stage.